ANVS
What one share of Annovis Bio holds
Pharmaceutical Preparations
We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases.
Annovis Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.79 |
| Cash and investments | $0.44 |
| Book value | −$0.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.00 | −$3.51 | — | −$1.69 | — | −$30.35 |
| 2020 | $0.00 | −$0.87 | — | −$0.63 | — | $1.09 |
| 2021 | $0.00 | −$1.90 | — | −$1.20 | — | $5.49 |
| 2022 | $0.00 | −$3.10 | — | −$2.12 | — | $3.47 |
| 2023 | $0.00 | −$6.23 | — | −$4.43 | — | −$0.74 |
| 2024 | $0.00 | −$2.31 | — | −$1.79 | — | $0.66 |
| 2025 | $0.00 | −$1.40 | — | −$1.25 | — | $0.62 |